News | February 27, 2026
Novo Nordisk slashes prices of Wegovy & Ozempic by up to 50%
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
Subscribe To Our Newsletter & Stay Updated
